Economic burden of cardiovascular diseases in the European Union: a population-based cost study.
Cardiovascular disease
Cerebrovascular disease
Coronary heart disease
Cost
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
27
07
2023
revised:
15
08
2023
accepted:
24
08
2023
medline:
4
12
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) impacts significantly health and social care systems as well as society through premature mortality and disability, with patients requiring care from relatives. Previous pan-European estimates of the economic burden of CVD are now outdated. This study aims to provide novel, up-to-date evidence on the economic burden across the 27 European Union (EU) countries in 2021. Aggregate country-specific resource use data on morbidity, mortality, and health, social and informal care were obtained from international sources, such as the Statistical Office of the European Communities, enhanced by data from the European Society of Cardiology Atlas programme and patient-level data from the Survey of Health, Ageing and Retirement in Europe. Country-specific unit costs were used, with cost estimates reported on a per capita basis, after adjustment for price differentials. CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equalling 11% of EU-health expenditure. Productivity losses accounted for 17% (€48 billion), whereas informal care costs were €79 billion (28%). CVD represented a cost of €630 per person, ranging from €381 in Cyprus to €903 in Germany. Coronary heart disease accounted for 27% (€77 billion) and cerebrovascular diseases for 27% (€76 billion) of CVD costs. This study provides contemporary estimates of the wide-ranging impact of CVD on all aspects of the economy. The data help inform evidence-based policies to reduce the impact of CVD, promoting care access and better health outcomes and economic sustainability.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Cardiovascular disease (CVD) impacts significantly health and social care systems as well as society through premature mortality and disability, with patients requiring care from relatives. Previous pan-European estimates of the economic burden of CVD are now outdated. This study aims to provide novel, up-to-date evidence on the economic burden across the 27 European Union (EU) countries in 2021.
METHODS
METHODS
Aggregate country-specific resource use data on morbidity, mortality, and health, social and informal care were obtained from international sources, such as the Statistical Office of the European Communities, enhanced by data from the European Society of Cardiology Atlas programme and patient-level data from the Survey of Health, Ageing and Retirement in Europe. Country-specific unit costs were used, with cost estimates reported on a per capita basis, after adjustment for price differentials.
RESULTS
RESULTS
CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equalling 11% of EU-health expenditure. Productivity losses accounted for 17% (€48 billion), whereas informal care costs were €79 billion (28%). CVD represented a cost of €630 per person, ranging from €381 in Cyprus to €903 in Germany. Coronary heart disease accounted for 27% (€77 billion) and cerebrovascular diseases for 27% (€76 billion) of CVD costs.
CONCLUSIONS
CONCLUSIONS
This study provides contemporary estimates of the wide-ranging impact of CVD on all aspects of the economy. The data help inform evidence-based policies to reduce the impact of CVD, promoting care access and better health outcomes and economic sustainability.
Identifiants
pubmed: 37632363
pii: 7251239
doi: 10.1093/eurheartj/ehad583
pmc: PMC10691195
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4752-4767Subventions
Organisme : European Society of Cardiology
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Eur J Health Econ. 2006 Mar;7(1):7-18
pubmed: 16429295
Eur Heart J. 2022 Feb 22;43(8):716-799
pubmed: 35016208
Eur J Public Health. 2014 Dec;24(6):1023-8
pubmed: 24627542
Eur Heart J Qual Care Clin Outcomes. 2023 Jun 06;:
pubmed: 37280170
Circulation. 2023 Feb 21;147(8):e93-e621
pubmed: 36695182
Eur Heart J Qual Care Clin Outcomes. 2023 Jun 21;9(4):377-388
pubmed: 36385522
Eur J Neurol. 2012 Jan;19(1):149-54
pubmed: 21951976
Eur Urol. 2016 Mar;69(3):438-47
pubmed: 26508308
N Engl J Med. 1999 Jun 17;340(24):1881-7
pubmed: 10369852
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
Int J Epidemiol. 2013 Aug;42(4):992-1001
pubmed: 23778574
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614
BMJ Open. 2015 Apr 13;5(4):e006648
pubmed: 25869683
Lancet Haematol. 2016 Aug;3(8):e362-70
pubmed: 27476787
Lancet Haematol. 2016 Aug;3(8):e371-8
pubmed: 27476788
Stroke. 2013 Oct;44(10):2854-61
pubmed: 23920019
Eur Heart J. 2006 Jul;27(13):1610-9
pubmed: 16495286
Int J Cardiol. 2016 Jul 15;215:332-7
pubmed: 27128556
J Alzheimers Dis. 2011;27(1):187-96
pubmed: 21860095
Intern Emerg Med. 2023 Jan;18(1):137-149
pubmed: 36352300
Nat Cancer. 2021 Mar;2(3):245-246
pubmed: 35121963
Soc Sci Med. 1992 May;34(9):1005-10
pubmed: 1631600